

## Diagnosis in Oncology

6. Bernard GR, Artigas A, Brigham KL, et al: Report of the American-European consensus conference on ARDS: Definitions, mechanisms, relevant outcomes and clinical trial coordination—The Consensus Committee. *Intensive Care Med* 20:225-232, 1994
7. Okamoto I, Fujii K, Matsumoto M, et al: Diffuse alveolar damage after ZD1839 therapy in a patient with non-small cell lung cancer. *Lung Cancer* 40:339-342, 2003
8. Inoue A, Saijo Y, Maemondo M, et al: Severe acute interstitial pneumonia and gefitinib. *Lancet* 361:137-139, 2003
9. Soda M, Choi YL, Enomoto M, et al: Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. *Nature* 448:561-566, 2007
10. Soda M, Takada S, Takeuchi K, et al: A mouse model for EML4-ALK-positive lung cancer. *Proc Natl Acad Sci U S A* 105:19893-19897, 2008
11. Takezawa K, Okamoto I, Nishio K, et al: Role of ERK-BIM and STAT3-survivin signaling pathways in ALK inhibitor-induced apoptosis in EML4-ALK-positive lung cancer. *Clin Cancer Res* 17:2140-2148, 2011
12. Ando M, Okamoto I, Yamamoto N, et al: Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib. *J Clin Oncol* 24:2549-2556, 2006

DOI: 10.1200/JCO.2012.43.3730; published online ahead of print at [www.jco.org](http://www.jco.org) on November 19, 2012



